Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) EBIT Margin: 2019-2023

Historic EBIT Margin for Benitec Biopharma (BNTC) over the last 2 years, with Jun 2023 value amounting to -65,000.00%.

  • Benitec Biopharma's EBIT Margin was N/A to -65,000.00% in Q2 2023 from the same period last year, while for Jun 2023 it was -15,513.01%, marking a year-over-year change of. This contributed to the annual value of -25,441.33% for FY2023, which is 98380.00% down from last year.
  • Latest data reveals that Benitec Biopharma reported EBIT Margin of -65,000.00% as of Q2 2023, which was down 708.57% from -8,038.89% recorded in Q1 2023.
  • In the past 5 years, Benitec Biopharma's EBIT Margin ranged from a high of 8,248.57% in Q2 2020 and a low of -379,300.00% during Q1 2021.
  • Its 3-year average for EBIT Margin is -101,672.66%, with a median of -40,071.43% in 2022.
  • In the last 5 years, Benitec Biopharma's EBIT Margin crashed by 37,176,071bps in 2021 and then skyrocketed by 37,209,167bps in 2022.
  • Benitec Biopharma's EBIT Margin (Quarterly) stood at -2,741.56% in 2019, then slumped by 32,315,844bps to -325,900.00% in 2020, then skyrocketed by 30,656,000bps to -19,340.00% in 2021, then tumbled by 2,073,143bps to -40,071.43% in 2022, then tumbled by 83,056bps to -65,000.00% in 2023.
  • Its EBIT Margin stands at -65,000.00% for Q2 2023, versus -8,038.89% for Q1 2023 and -40,071.43% for Q4 2022.